Viral respiratory tract infection is the most common illness among humans. Probiotics have been known to enhance the immune system and, therefore, may represent a significant therapeutic advancement for treating viral respiratory tract infections. A controlled study was conducted to evaluate the effects of the patented GanedenBC30 probiotic (Bacillus coagulans) on the immune system when exposed to adenovirus and influenza in otherwise healthy adults…

No serious adverse events were reported throughout the study. The patented GanedenBC30 probiotic may be a safe and effective therapeutic option for enhancing T-cell response to certain viral respiratory tract infections.